Efficacy and safety of peptide receptor radionuclide therapy with [ 177 Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma.

MLA

Minczeles, Noémie S., et al. “Efficacy and Safety of Peptide Receptor Radionuclide Therapy with [ 177 Lu]Lu-DOTA-TATE in 15 Patients with Progressive Treatment-Refractory Meningioma.” European Journal of Nuclear Medicine and Molecular Imaging, vol. 50, no. 4, Mar. 2023, pp. 1195–204. EBSCOhost, https://doi.org/10.1007/s00259-022-06044-9.

APA

Minczeles, N. S., Bos, E. M., de Leeuw, R. C., Kros, J. M., Konijnenberg, M. W., Bromberg, J. E. C., de Herder, W. W., Dirven, C. M. F., Hofland, J., & Brabander, T. (2023). Efficacy and safety of peptide receptor radionuclide therapy with [ 177 Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma. European Journal of Nuclear Medicine and Molecular Imaging, 50(4), 1195–1204. https://doi.org/10.1007/s00259-022-06044-9

Chicago

Minczeles, Noémie S, Eelke M Bos, Reinoud C de Leeuw, Johan M Kros, Mark W Konijnenberg, Jacoline E C Bromberg, Wouter W de Herder, Clemens M F Dirven, Johannes Hofland, and Tessa Brabander. 2023. “Efficacy and Safety of Peptide Receptor Radionuclide Therapy with [ 177 Lu]Lu-DOTA-TATE in 15 Patients with Progressive Treatment-Refractory Meningioma.” European Journal of Nuclear Medicine and Molecular Imaging 50 (4): 1195–1204. doi:10.1007/s00259-022-06044-9.